ReAlta Life Sciences has announced the closing of an oversubscribed $40 million financing, bringing the total capital raised to date to more than $150 million. The company will use the proceeds to advance pegtarazimod through key clinical and regulatory milestones as the first potential treatment for Hypoxic… Read More
The European Medicines Agency (EMA) has granted orphan drug designation to ReAlta’s RLS-0071 (pegtarazimod) for the treatment of graft-versus-host disease (GvHD). The Orphan Drug Designation was supported by preliminary data from ReAlta’s ongoing Phase II trial, which included data from the initial cohort of steroid-refractory acute GvHD… Read More
A new study has shown that pegtarazimod reduces microglial activation associated with pathogenic neuroinflammation in hypoxic ischaemic encephalopathy (HIE), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. The article in the American Journal of Perinatology highlights that pegtarazimod reduces… Read More
